The lack of consistent testing in measuring product quality for cell and gene therapies is a major deficiency found by US Food and Drug Administration (FDA) reviewers in its information requests (IRs) ...
Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the ...
Early Access Program delivers hands-on access to capabilities designed to close the Training/Testing Gap and validate resilience across people, processes, technologies, and AI. AI-driven threats adapt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results